Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
Bhatu Patil, Kunal Bhadane, Iqrar Ahmad, Yogesh Agrawal, Amit Shimpi, Mayur S. Dhangar, Harun Patel
Topics & Concepts
OsimertinibT790MChemistryLung cancerCancer researchMutantPharmacologyEpidermal growth factor receptorBiochemistryReceptorMedicineOncologyErlotinibGeneGefitinibLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancerCancer therapeutics and mechanisms